Botulinum toxin type A (BTA) injections, with or without sodium hyaluronate (SH), are effective and feasible for the treatment of infantile esotropia.
Botulinum toxin type A (BTA) injections, with or without sodium hyaluronate (SH), are effective and feasible for the treatment of infantile esotropia, claims a paper in the journal Eye.
The investigation, led by Dr J. Chen, State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Centre, Sun Yat-sen University, Guangzhou, China, included 47 patients with infantile esotropia who were randomly divided into two groups. Group A included 23 cases treated with bilateral injection of 2.5–3.75 U BTA combined with sodium hyaluronate (SH). In group B 24 patients were administered the BTA solution with SH. All patients did not undergo electromyography and injections were evaluated two weeks, three months and six months postoperatively.
Both groups presented with good alignment six months after injections, with group A at 30.4% and group B at 37.5%. Complicated ptosis and vertical deviation were 2.2% vs 20.8% and 2.2% vs 2.1% in groups A and B, respectively.
BTA injections with or without SH produced similar results and demonstrated effectiveness and feasibility. However, BTA injections with SH relatively decrease the frequency of complicated ptosis.
The abstract can be read here.
AAO 2023: Company updates from Centricity Vision CEO Rob Thornhill
November 28th 2023At this year's American Academy of Ophthalmology meeting in San Francisco, California, Rob Thornhill, CEO of Centricity Vision, spoke with the Ophthalmology Times team about developments in the company's ZEPTOLink IOL positioning systems.
AAO 2023: Marco A. Zarbin, MD, PhD, provides analysis of the YOSEMITE and RHINE clinical trials
November 24th 2023At this year's American Academy of Ophthalmology meeting in San Francisco, California, Marco A. Zarbin, MD, spoke with Ophthalmology Times about his team's post-hoc analysis of the YOSEMITE and RHINE clinical trials